Phase 3 Pancreatic Ductal Adenocarcinoma Clinical Trials
17 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–17 of 17 trials
Recruiting
Phase 2Phase 3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal AdenocarcinomaPDAC
AbbVie900 enrolled11 locationsNCT07490301
Recruiting
Phase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.670 enrolled3 locationsNCT07621718
Recruiting
Phase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled17 locationsNCT07562152
Recruiting
Phase 2Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled188 locationsNCT06989437
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled5 locationsNCT07491445
Recruiting
Phase 3
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE200 enrolled14 locationsNCT07217717
Recruiting
Phase 3
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.566 enrolled71 locationsNCT07165951
Recruiting
Phase 2Phase 3
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
Gastric CancersColorectal, CancerPancreatic Ductal Adenocarcinoma+1 more
GE Healthcare175 enrolled2 locationsNCT07219238
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+1 more
NRG Oncology356 enrolled279 locationsNCT06958328
Recruiting
Phase 3
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Pancreatic CancerCholangiocarcinomaPancreatic Ductal Adenocarcinoma+4 more
Minia University194 enrolled1 locationNCT07155525
Recruiting
Phase 2Phase 3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Gastric CancerPancreatic Ductal AdenocarcinomaOncology+3 more
KU Leuven109 enrolled3 locationsNCT06782412
Recruiting
Phase 2Phase 3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Pancreatic Ductal AdenocarcinomaPancreatic Cancer Stage IVPancreatic Cancer Metastatic
Panbela Therapeutics, Inc.600 enrolled93 locationsNCT05254171
Recruiting
Phase 3
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
Pancreatic CancerPancreatic Ductal AdenocarcinomaResectable Pancreatic Adenocarcinoma
Erasmus Medical Center378 enrolled22 locationsNCT04927780
Recruiting
Phase 2Phase 3
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Oncotelic Inc.455 enrolled2 locationsNCT06079346
Recruiting
Phase 3
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
GC Cell Corporation408 enrolled1 locationNCT04969731